新华制药
(000756)
| 流通市值：71.49亿 | | | 总市值：99.83亿 |
| 流通股本：4.99亿 | | | 总股本：6.97亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,357,548,611.17 | 2,423,049,619.1 | 8,754,721,987.78 | 6,762,620,901.32 |
| 营业收入 | 4,357,548,611.17 | 2,423,049,619.1 | 8,754,721,987.78 | 6,762,620,901.32 |
| 二、营业总成本 | 4,159,524,749.7 | 2,313,460,629.83 | 8,390,212,699.23 | 6,434,132,318.5 |
| 营业成本 | 3,522,514,897.69 | 1,981,945,053.94 | 7,110,179,626.73 | 5,466,108,298.73 |
| 税金及附加 | 39,139,782.42 | 22,865,468.49 | 65,098,579.77 | 49,992,363.37 |
| 销售费用 | 167,749,175.94 | 103,476,027.03 | 341,082,001.85 | 270,217,382.23 |
| 管理费用 | 206,930,932.69 | 94,907,605.7 | 457,662,218.64 | 326,735,663.65 |
| 研发费用 | 192,694,792.28 | 95,473,864.96 | 381,617,425.73 | 300,109,321.29 |
| 财务费用 | 30,495,168.68 | 14,792,609.71 | 34,572,846.51 | 20,969,289.23 |
| 其中:利息费用 | 17,264,463.43 | 8,449,572.07 | 42,431,327.39 | 28,761,123.36 |
| 其中:利息收入 | 2,621,550.54 | 1,165,719.39 | 7,685,444.95 | 4,427,041.36 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 7,363,123.47 | 333,529.89 | 7,764,521.27 | 6,102,717.35 |
| 资产处置收益 | 93,383.69 | 108,900.17 | 1,990,589.09 | 1,833,484.62 |
| 资产减值损失(新) | -40,425,032.15 | - | -47,394,139.35 | -50,287,533.79 |
| 信用减值损失(新) | -6,248,825.3 | 50,250 | -5,351,752.99 | -9,035,931.3 |
| 其他收益 | 16,853,626.8 | 8,951,288.61 | 42,466,344.69 | 34,700,384.05 |
| 四、营业利润 | 175,660,137.98 | 119,032,957.94 | 363,984,851.26 | 311,801,703.75 |
| 加:营业外收入 | 1,789,050.85 | 676,607.62 | 5,415,769.48 | 2,664,909.2 |
| 减:营业外支出 | 12,506,676.44 | 1,076,787.65 | 10,484,117.56 | 8,470,033.58 |
| 五、利润总额 | 164,942,512.39 | 118,632,777.91 | 358,916,503.18 | 305,996,579.37 |
| 减:所得税费用 | 16,987,719.37 | 35,365,534.05 | 52,612,585.03 | 39,087,967.8 |
| 六、净利润 | 147,954,793.02 | 83,267,243.86 | 306,303,918.15 | 266,908,611.57 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 147,954,793.02 | 83,267,243.86 | 306,303,918.15 | 266,908,611.57 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 149,127,526.81 | 83,903,044.36 | 289,888,855 | 256,220,710.12 |
| 少数股东损益 | -1,172,733.79 | -635,800.5 | 16,415,063.15 | 10,687,901.45 |
| 扣除非经常损益后的净利润 | 147,309,628.75 | 80,291,736.33 | 268,343,425.04 | 239,056,816.15 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.21 | 0.12 | 0.42 | 0.37 |
| (二)稀释每股收益 | 0.21 | 0.12 | 0.42 | 0.37 |
| 八、其他综合收益 | -65,971,211.38 | -23,698,036.77 | 26,020,010.31 | -5,083,975.62 |
| 归属于母公司股东的其他综合收益 | -65,449,015.5 | -23,434,398.84 | 26,360,028.52 | -4,853,738.45 |
| 九、综合收益总额 | 81,983,581.64 | 59,569,207.09 | 332,323,928.46 | 261,824,635.95 |
| 归属于母公司股东的综合收益总额 | 83,678,511.31 | 60,468,645.52 | 316,248,883.52 | 251,366,971.67 |
| 归属于少数股东的综合收益总额 | -1,694,929.67 | -899,438.43 | 16,075,044.94 | 10,457,664.28 |
| 公告日期 | 2026-08-26 | 2026-04-29 | 2026-03-30 | 2025-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |